Effectiveness of COVID boosters in MS: an update


Two recent studies have reported that COVID boosters can increase the humoral response in MS patients during treatment with ocrelizumab or fingolimod. A number of studies have reported that these disease-modifying therapies (DMT) are associated with a blunted humoral response to COVID vaccination (Achiron et al. Ther Adv Neurol Disord 2021;14:17562864211012835. Gallo et al. Neurol Sci 2021;42:3523-3526). Read More

SPMS pathogenesis and treatment


ECTRIMS Special Report

Secondary-progressive multiple sclerosis (SPMS) was an area of special interest at the recent European Committee for Treatment and Research in MS (ECTRIMS) annual meeting, held October 26-28 in Amsterdam, The Netherlands. Read More



Selected highlights from the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Amsterdam, The Netherlands
26-28 October 2022
62 slides with notes

Scientific review:
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada Read More